Xspray Pharma AB (publ) (XSPRAY.ST)
SEK 41.5
(-5.36%)
SEK 41.5
(-5.36%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 765.26 Million SEK | 30.72% |
| 2022 | 585.43 Million SEK | -6.02% |
| 2021 | 622.9 Million SEK | 2.91% |
| 2020 | 605.3 Million SEK | 51.07% |
| 2019 | 400.67 Million SEK | 28.22% |
| 2018 | 312.48 Million SEK | 93.59% |
| 2017 | 161.41 Million SEK | 211.24% |
| 2016 | 51.86 Million SEK | 246.88% |
| 2015 | 14.95 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 705.41 Million SEK | -7.82% |
| 2024 Q2 | 736.06 Million SEK | 4.35% |
| 2023 Q2 | 561.12 Million SEK | 2.42% |
| 2023 Q1 | 547.84 Million SEK | -6.42% |
| 2023 Q4 | 765.26 Million SEK | 8.81% |
| 2023 Q3 | 703.3 Million SEK | 25.34% |
| 2023 FY | 765.26 Million SEK | 30.72% |
| 2022 Q2 | 566.34 Million SEK | -4.4% |
| 2022 Q3 | 539.96 Million SEK | -4.66% |
| 2022 Q1 | 592.43 Million SEK | -4.89% |
| 2022 FY | 585.43 Million SEK | -6.02% |
| 2022 Q4 | 585.43 Million SEK | 8.42% |
| 2021 FY | 622.9 Million SEK | 2.91% |
| 2021 Q2 | 578.74 Million SEK | -2.6% |
| 2021 Q3 | 566.74 Million SEK | -2.07% |
| 2021 Q4 | 622.9 Million SEK | 9.91% |
| 2021 Q1 | 594.17 Million SEK | -1.84% |
| 2020 Q4 | 605.3 Million SEK | 64.62% |
| 2020 FY | 605.3 Million SEK | 51.07% |
| 2020 Q3 | 367.7 Million SEK | 0.57% |
| 2020 Q2 | 365.63 Million SEK | -4.55% |
| 2020 Q1 | 383.06 Million SEK | -4.4% |
| 2019 Q3 | 292.23 Million SEK | -3.39% |
| 2019 FY | 400.67 Million SEK | 28.22% |
| 2019 Q1 | 307.37 Million SEK | -1.63% |
| 2019 Q2 | 302.49 Million SEK | -1.59% |
| 2019 Q4 | 400.67 Million SEK | 37.1% |
| 2018 Q4 | 312.48 Million SEK | 35.26% |
| 2018 FY | 312.48 Million SEK | 93.59% |
| 2018 Q1 | 241.49 Million SEK | 49.61% |
| 2018 Q2 | 235.92 Million SEK | -2.31% |
| 2018 Q3 | 231.02 Million SEK | -2.08% |
| 2017 Q2 | 43.67 Million SEK | 0.0% |
| 2017 Q3 | 175.62 Million SEK | 302.13% |
| 2017 Q4 | 161.41 Million SEK | -8.09% |
| 2017 FY | 161.41 Million SEK | 211.24% |
| 2017 Q1 | - SEK | -100.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 Q4 | 51.86 Million SEK | 0.0% |
| 2016 FY | 51.86 Million SEK | 246.88% |
| 2015 FY | 14.95 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 118.45 Million SEK | -546.064% |
| Ziccum AB (publ) | 14.97 Million SEK | -5011.294% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -3718.487% |
| BioArctic AB (publ) | 1.18 Billion SEK | 35.48% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -1126.835% |
| Mendus AB (publ) | 755.95 Million SEK | -1.232% |
| Genovis AB (publ.) | 288.85 Million SEK | -164.928% |
| Intervacc AB (publ) | 259.61 Million SEK | -194.773% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -1723.835% |
| Active Biotech AB (publ) | 44 Million SEK | -1639.234% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | -174.539% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -1131.277% |
| Aptahem AB (publ) | 63.02 Million SEK | -1114.222% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | -54.21% |
| Kancera AB (publ) | 65.64 Million SEK | -1065.795% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | -117.816% |
| Fluicell AB (publ) | 9.34 Million SEK | -8093.394% |
| Saniona AB (publ) | 64.14 Million SEK | -1093.058% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -2177.433% |
| Biovica International AB (publ) | 131.4 Million SEK | -482.356% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -1344.301% |
| AcouSort AB (publ) | 34.51 Million SEK | -2117.318% |
| Xintela AB (publ) | 18.39 Million SEK | -4060.169% |
| Abliva AB (publ) | 87.49 Million SEK | -774.596% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | -0.666% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 39.187% |
| OncoZenge AB (publ) | 20.34 Million SEK | -3662.355% |
| Amniotics AB (publ) | 26.08 Million SEK | -2833.616% |
| 2cureX AB (publ) | 16.62 Million SEK | -4503.086% |
| CombiGene AB (publ) | 120.61 Million SEK | -534.483% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -12492.776% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 59.735% |
| Camurus AB (publ) | 1.9 Billion SEK | 59.888% |
| Corline Biomedical AB | 100.1 Million SEK | -664.46% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | -332.057% |
| Isofol Medical AB (publ) | 140.59 Million SEK | -444.295% |
| I-Tech AB | 152.44 Million SEK | -401.999% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 24.83% |
| Cyxone AB (publ) | 43.65 Million SEK | -1652.979% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | -872.479% |
| Biosergen AB | 7.2 Million SEK | -10527.177% |
| Cantargia AB (publ) | 223.71 Million SEK | -242.075% |
| NextCell Pharma AB | 81.28 Million SEK | -841.422% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -2436.248% |
| Nanologica AB (publ) | 77.42 Million SEK | -888.342% |
| SynAct Pharma AB | 228.01 Million SEK | -235.614% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -2759.407% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -3426.09% |
| LIDDS AB (publ) | 17.65 Million SEK | -4234.54% |
| Lipum AB (publ) | 12.11 Million SEK | -6219.265% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 45.345% |
| Alzinova AB (publ) | 123.18 Million SEK | -521.21% |
| Oncopeptides AB (publ) | 238.37 Million SEK | -221.029% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -8951.011% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | -797.911% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -5046.701% |
| Simris Alg AB (publ) | 174.55 Million SEK | -338.415% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | -252.594% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | -17.101% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | -778.885% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -2584.38% |